Terms: = Ovarian epithelial cancer AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4 AND Prognosis
756 results:
1. Spotlight on Carcinosarcoma of the Ovary: A Scoping Review.
Gauci M; Calleja-Agius J
Acta Medica (Hradec Kralove); 2024; 67(1):1-11. PubMed ID: 39288440
[TBL] [Abstract] [Full Text] [Related]
2. Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer.
Vázquez Rojo J; Vázquez Reguera J; Sánchez del Río A
Rev Colomb Obstet Ginecol; 2024 Mar; 75(1):. PubMed ID: 39013201
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; ; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Gilks CB; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Soong TR; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
Clin Cancer Res; 2024 Aug; 30(16):3481-3498. PubMed ID: 38837893
[TBL] [Abstract] [Full Text] [Related]
4. epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract] [Full Text] [Related]
5. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
[No Abstract] [Full Text] [Related]
6. Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.
Azaïs H; Garinet S; Benoit L; de Jesus J; Zizi M; Landman S; Bats AS; Taly V; Laurent-Puig P; Blons H
J Gynecol Obstet Hum Reprod; 2024 Sep; 53(7):102796. PubMed ID: 38729429
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of ovarian cancer prognosis using statistical radiomic features of ultrasound images.
Zuo R; Li X; Hu J; Wang W; Lu B; Zhang H; Cheng X; Lu W; Qin J; Liu P; Lu Y
Phys Med Biol; 2024 Jun; 69(12):. PubMed ID: 38729170
[No Abstract] [Full Text] [Related]
8. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract] [Full Text] [Related]
9. Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series.
Matsuoka A; Tate S; Nishikimi K; Otsuka S; Usui H; Tajima S; Habu Y; Nakamura N; Okuya R; Katayama E; Shozu M; Inaba Y; Koga K
J Obstet Gynaecol Res; 2024 Jul; 50(7):1148-1154. PubMed ID: 38634254
[TBL] [Abstract] [Full Text] [Related]
10. Relationship between human epididymal protein 4 and depth of tumor invasion, postoperative recurrence, and metastasis of epithelial epithelial ovarian cancer.
Li Y; Yu C; Li H; Feng Y; Fan P; Chen X
Asia Pac J Clin Oncol; 2024 Aug; 20(4):472-480. PubMed ID: 38615275
[TBL] [Abstract] [Full Text] [Related]
11. Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study.
Yang EJ; Lee AJ; Hwang WY; Chang SJ; Kim HS; Kim NK; Kim Y; Kong TW; Lee EJ; Park SJ; Son JH; Suh DH; Son DH; Shim SH
J Gynecol Oncol; 2024 Jul; 35(4):e75. PubMed ID: 38497109
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
13. Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in ovarian cancer.
Uno K; Koya Y; Yoshihara M; Iyoshi S; Kitami K; Sugiyama M; Miyamoto E; Mogi K; Fujimoto H; Yamakita Y; Wang X; Nawa A; Kajiyama H
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338902
[TBL] [Abstract] [Full Text] [Related]
14. Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data.
Li K; Yin R
Front Immunol; 2024; 15():1346464. PubMed ID: 38312839
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of Fut 2, 4, and 8, and nuclear localization of Fut 4 in ovarian cancer cell lines induced by ascitic fluids from epithelial ovarian cancer patients.
Alvear-Hernandez NP; Hernández-Ramírez VI; Villegas-Pineda JC; Osorio-Trujillo JC; Guzmán-Mendoza JJ; Gallardo-Rincón D; Toledo-Leyva A; Talamás-Rohana P
Cell Biol Int; 2024 May; 48(5):610-625. PubMed ID: 38263584
[TBL] [Abstract] [Full Text] [Related]
16. CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer.
Shao D; Zhou H; Yu H; Zhu X
Medicine (Baltimore); 2024 Jan; 103(3):e36891. PubMed ID: 38241595
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
18. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract] [Full Text] [Related]
19. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
[TBL] [Abstract] [Full Text] [Related]
20. TGF-β-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer.
Wu J; Liao Q; Zhang LI; Wu S; Liu Z
Oncol Res; 2023; 32(2):373-391. PubMed ID: 38186569
[TBL] [Abstract] [Full Text] [Related]
[Next]
